ClinConnect ClinConnect Logo
Search / Trial NCT01087801

A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers

Launched by CHIRHOCLIN, INC. · Mar 15, 2010

Trial Information

Current as of October 11, 2025

Completed

Keywords

Genetic End Marker

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Documented or suspected diagnosis of chronic pancreatitis or suspected diagnosis of pancreatic cancer.
  • 2. Undergoing Endoscopic Procedure.
  • 3. Age ≥ 18 years.
  • 4. Willing and able to sign informed consent, meeting IRB guidelines.
  • 5. Willing and able to meet all study requirements and obligations.
  • Exclusion Criteria:
  • 1. Ongoing, active pancreatitis at the time of the procedure.
  • 2. Known adverse reaction to secretin.
  • 3. Recent (within one month) use of medication that can potentially cause pancreatitis, such as metronidazole, tetracycline, sulfonamides.
  • 4. Use of anticholinergic medication within 7 days of study.
  • 5. Pregnant women, nursing mothers, or women of childbearing potential not employing appropriate contraception. Acceptable methods of birth control are: intrauterine device, implantable progesterone device, progesterone intramuscular injection, oral contraceptive (started at least one month prior to Visit 1 and continuing for the duration of the trial), contraceptive patch, condoms with spermicide or abstinence.
  • 6. Any medical condition which in the judgment of the Principal Investigator makes participation of the patient in the study medically unwarranted.
  • 7. Known complete obstruction of the pancreatic duct.
  • 8. Patients who have received an investigational product/drug or device within 30 days prior to Visit 1.

About Chirhoclin, Inc.

Chirhoclin, Inc. is a clinical trial sponsor dedicated to advancing innovative therapies in the field of healthcare. With a focus on enhancing patient outcomes, the company specializes in conducting rigorous clinical studies that adhere to the highest ethical and regulatory standards. Leveraging a team of experienced professionals and state-of-the-art technology, Chirhoclin, Inc. collaborates with leading researchers and healthcare institutions to bring cutting-edge treatments from the laboratory to the clinic. Committed to scientific excellence and patient safety, Chirhoclin, Inc. aims to contribute significantly to the development of new medical solutions that address unmet clinical needs.

Locations

Saint Louis, Missouri, United States

Patients applied

0 patients applied

Trial Officials

Frank Burton, M.D.

Principal Investigator

St. Louis University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials